Patients’ Preferred Endpoints May Not Satisfy Regulatory Needs, US FDA Says

 
• By Sue Sutter
  
Business_Man_Ceiling
Sponsors may face patient community pressure to use an outcome assessment not well-suited to detecting clinically meaningful change. • Source: Shutterstock

More from Rare Diseases

More from Pink Sheet